

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-28 (Cancelled)

-29- (Currently amended)

A method for producing an antibody for use as a passive immunity vaccine in horses against a *Sarcocystis neurona* antigen selected from the group consisting of a 16 (+/-4) kDa antigen and a 30 (+/-4) kDa antigen, as determined by SDS polyacrylamide gel electrophoresis, comprising:

(a) providing a *Sarcocystis neurona* antigen selected from the group consisting of the 16 (+/-4) kDa antigen and the 30 (+/-4) kDa antigen;

(b) admixing the antigen with an adjuvant to produce an admixture;

(c) immunizing a mammal with the admixture to produce antibodies against antigen; ~~and~~

(d) removing serum from the immunized mammal and isolating from the serum the antibody against the *Sarcocystis neurona* antigen selected from the group consisting of the (+/-4) 16 kDa antigen and the (+/-4)

30 kDa antigen; and

20 (e) providing the isolated antibodies to the
16 and 30 kDa together as the passive immunity vaccine
in horses.

-30- (Currently amended)

A method for producing a monoclonal antibody
for use in a passive immunity vaccine in horses against
a *Sarcocystis neurona* antigen selected from the group
consisting of a 16 (+/-4) kDa antigen and a 30 (+/-4)
5 kDa antigen, as determined by SDS polyacrylamide gel
electrophoresis, comprising:

(a) providing a microorganism containing a DNA
encoding a fusion polypeptide linked to ~~in which~~ a
Sarcocystis neurona antigen selected from the group
10 consisting of the 16 (+/-4) kDa antigen and the 30 (+/-
4) kDa antigen;

(b) admixing the polypeptide ~~antigen~~ with an
adjuvant to produce an admixture;

(c) inoculating mice with the admixture to
15 produce antibodies against antigen;

(d) removing the spleens from the mice which
produce the antibodies against the antigen;

(e) removing spleen cells from the spleens and mixing the spleen cells from the spleens with mouse myeloma cells to produce a mixture of fused cells consisting of spleen cells fused to myeloma cells, the spleen cells, and the myeloma cells;

(f) selecting the fused cells on cell culture medium in which the fused cells can grow but in which the spleen cells and the myeloma cells cannot grow; and

(g) screening the fused cells for fused cells which produce the monoclonal antibody against the *Sarcocystis neurona* antigen selected from the group consisting of the 16 (+/-4) kDa antigen and the 30 (+/-4) kDa antigen to produce the monoclonal antibody; and

(h) providing the monoclonal antibodies as a mixture together as the passive immunity vaccine in horses.

Claim 31 (Cancelled)

Claims 32-35 (Cancelled)

Claims 36-50 (Cancelled)